See more : Creative Eye Limited (CREATIVEYE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Outlook Therapeutics, Inc. (OTLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outlook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Equitable Financial Corp. (EQFN) Income Statement Analysis – Financial Results
- GWG Holdings, Inc. (GWGH) Income Statement Analysis – Financial Results
- Skye Bioscience, Inc. (SKYE) Income Statement Analysis – Financial Results
- Paramount Global (PARAP) Income Statement Analysis – Financial Results
- Bowhead Specialty Holdings Inc. (BOW) Income Statement Analysis – Financial Results
Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 23.81K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | 0.00 | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.71% | 99.40% | 99.38% | 98.90% | 99.26% | 99.84% |
| Research & Development | 41,763.05B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| General & Administrative | 29,940.19B | 26.67M | 20.74M | 12.77M | 9.97M | 9.37M | 14.23M | 15.88M | 21.64M | 12.91M | 7.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | 0.00 | 0.00 |
| SG&A | 29,940.19B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Other Expenses | 0.00 | 0.00 | -882.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71,703.24B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Cost & Expenses | 0.00 | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3,156.96B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Depreciation & Amortization | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |
| EBITDA | -71,703.24B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -265.98% | -725.17% | -870.73% | -1,656.75% | -857.18% | -127.22% |
| Operating Income | -71,703.24B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -445.60% | -824.09% | -941.36% | -1,737.10% | -892.13% | -136.92% |
| Total Other Income/Expenses | -3,660.68B | -5.85M | -2.98M | -1.43M | -1.67M | -1.64M | -4.10M | -2.47M | -1.85M | -2.30M | -901.05K |
| Income Before Tax | -75,363.91B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -465.68% | -1,092.78% | -1,006.10% | -1,786.37% | -936.15% | -146.88% |
| Income Tax Expense | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Net Income | -75,366.71B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -423.81% | -1,493.57% | -1,019.26% | -1,789.83% | -908.05% | -151.73% |
| EPS | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.54 | -495.71 | -504.47 | -155.35 |
| Weighted Avg Shares Out | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Weighted Avg Shares Out (Dil) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Outlook Therapeutics, Inc. (“Outlook” or...
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Outlook securities between August 3, 2021 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310)....
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or "the Company") (NASDAQ:OTLK) for violations of 10(b)...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLK
NEW YORK , Dec. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, both dates inclusive (the...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Dec. 26, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of...
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
ISELIN, N.J., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve U.S. Food and Drug Administration (FDA) approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or "the Company") (NASDAQ:OTLK) for violations of 10(b)...
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in Outlook securities between December 29, 2022 and August 29, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310)....
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Dec. 20, 2023 /PRNewswire/ -- Law Offices of Howard G.
Source: https://incomestatements.info
Category: Stock Reports